FrancophonIA/ELRC3.0 huggingface dataset:
English: Serious adverse reactions associated with cangrelor in patients with coronary artery disease include severe/life threatening bleeding and hypersensitivity.
Slovenian: Resni neželeni učinki, povezani s kangrelorjem pri bolnikih z boleznijo koronarnih arterij, vključujejo hudo/življenjsko nevarno krvavitev in preobčutljivost.
English: Do not use this medicine after the expiry date which is stated on the label and carton after ‘EXP'.
Slovenian: Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki in škatli poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
English: The European Medicines Agency has deferred the obligation to submit the results of studies with Kengrexal in one or more subsets of the paediatric population in the prevention of non-site specific embolism and thrombosis, for the treatment of thrombosis in paediatric patients undergoing diagnostic and / or therapeutic percutaneous vascular procedures.
Slovenian: Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom Kengrexal za eno ali več podskupin pediatrične populacije za preprečevanje embolije in tromboze, nespecifične za mesto, za zdravljenje tromboze pri pediatrični populaciji zaradi diagnostičnih in/ali terapevtskih perkutanih žilnih postopkov.
English: The pharmacokinetic/pharmacodynamic (PK/PD) effect of cangrelor is maintained consistently for the duration of the infusion.
Slovenian: Farmakokinetični/farmakodinamični (FK/FD) učinek kangrelorja se dosledno ohranja ves čas infundiranja.
English: • infection of bleeding sites,
Slovenian: • okužba mest krvavitev;
English: Other medicines and Kengrexal
Slovenian: Druga zdravila in zdravilo Kengrexal
English: Ensure that the contents of the vial are fully dissolved and the reconstituted material is a clear, colourless to pale yellow solution.
Slovenian: Prepričajte se, da je vsebina viale povsem raztopljena in da je rekonstituiran material bistra, brezbarvna do bledo-rumena raztopina.
English: No clinically relevant interruption of P2Y12 inhibition was observed in phase III studies when 600 mg clopidogrel was administered immediately after discontinuation of the cangrelor infusion.
Slovenian: Klinično pomembnega zaviranja P2Y12 v študijah III. faze niso opazili, ko so 600 mg klopidogrela dajali takoj po prekinitvi infundiranja kangrelorja.
English: An analysis of non-coronary artery bypass grafting (CABG)-related bleeding is presented in Table 2.
Slovenian: Analiza krvavitev, ki ni povezana s kirurškim posegom aortokoronarnega obvoda (CABG-Coronary Artery Bypass Graft), je predstavljena v preglednici 2.
English: In patients undergoing PCI, standard procedural adjunctive therapy should be implemented (see section 5.1).
Slovenian: Pri bolnikih pred PKI je treba uvesti standardno dopolnilno zdravljenje (glejte poglavje 5.1).
English: Cangrelor is rapidly distributed reaching Cmax within two minutes after administration of an intravenous bolus followed by infusion.
Slovenian: Kangrelor se hitro porazdeli in doseže Cmax v dveh minutah po apliciranju intravenskega bolusa, ki mu sledi infundiranje.
English: • Any history of stroke or transient ischaemic attack (TIA).
Slovenian: • Možganska kap ali tranzitorna ishemična ataka (TIA) v anamnezi.
English: Patients with coronary atherosclerosis were included who required PCI for stable angina (58%), non-ST-segment elevation acute coronary syndrome (NSTE-ACS) (26%), or ST-elevation myocardial infraction (STEMI) (16%).
Slovenian: Vključeni so bili bolniki s koronarno aterosklerozo, pri katerih je bila PKI potrebna zaradi stabilne angine pektoris (58 %), akutnega koronarnega sindroma brez elevacije spojnice ST (NSTE-ACS-non-ST-segment elevation acute coronary syndrome) (26 %) ali miokardnega infarkta z elevacijo spojnice ST (STEMI-ST-elevation myocardial infraction) (16 %).
English: Bivalirudin, low molecular weight heparin, fondaparinux, and GP IIb/IIIa inhibitors
Slovenian: Bivalirudin, nizkomolekularni heparin, fondaparinuks in zaviralci GP IIb/IIIa
English: Ensure the bolus is completely administered before the start of PCI.
Slovenian: Prepričajte se, da je bolus stekel do konca, preden začnete s PKI.
English: Kengrexal has no or negligible influence on the ability to drive and use machines.
Slovenian: Zdravilo Kengrexal nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
English: If side effects occur, they may need medical attention.
Slovenian: Če se pojavijo neželeni učinki, jih bo morda moral obravnavati zdravnik.
English: Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable.
Slovenian: Zdravilo Kengrexal, uporabljeno sočasno z acetilsalicilno kislino, je indicirano za zmanjšanje trombotičnih kardiovaskularnih dogodkov pri odraslih bolnikih z boleznijo koronarnih arterij med perkutano koronarno intervencijo (PKI), ki pred postopkom PKI niso prejemali peroralnega zaviralca P2Y12 in pri katerih peroralno zdravljenje z zaviralci P2Y12 ni možno ali ni zaželeno.
English: No dose adjustment is needed in patients with mild, moderate or severe renal insufficiency (see sections 4.4 and 5.2).
Slovenian: Pri bolnikih z blago, zmerno ali hudo ledvično insuficienco odmerka ni treba prilagajati (glejte poglavji 4.4 in 5.2).
English: Patients should be transitioned to oral P2Y12 therapy for chronic treatment.
Slovenian: Bolniki morajo preiti na peroralno zdravljenje s P2Y12 za dolgotrajno zdravljenje.
English: Oral P2Y12 agents (clopidogrel, prasugrel, ticagrelor)
Slovenian: Peroralna zdravila P2Y12 (klopidogrel, prasugrel, tikagrelor)
English: In CHAMPION PHOENIX, cangrelor significantly reduced (relative risk reduction 22%; absolute risk reduction 1.2%) the primary composite endpoint of all-cause mortality, MI, IDR, and ST compared to clopidogrel at 48 hours (Table 3).
Slovenian: V študiji CHAMPION PHOENIX je kangrelor po 48 urah pomembno zmanjšal (relativno zmanjšanje tveganja 22 %; absolutno zmanjšanje tveganja 1,2 % ) primarni sestavljeni opazovani dogodek, ki je zajemal smrtnost iz vseh vzrokov, MI, IDR in ST, v primerjavi s klopidogrelom (preglednica 3).
English: You may receive acetylsalicylic acid (ASA) while you are treated with Kengrexal or another type of anti-platelet medicine (e.g., clopidogrel) before and after you are treated with Kengrexal.
Slovenian: Med zdravljenjem z zdravilom Kengrexal lahko dobivate acetilsalicilno kislino ali kakšno drugo vrsto antitrombotika (npr. klopidogrel) pred zdravljenjem z zdravilom Kengrexal in po njem.
English: The primary clinical evidence for the efficacy of cangrelor is derived from CHAMPION PHOENIX, a randomised, double-blind study comparing cangrelor (n=5,472) to clopidogrel (n=5,470), both given in combination with aspirin and other standard therapy, including unfractionated heparin (78%), bivalirudin (23%), LMWH (14%) or fondaparinux (2.7%).
Slovenian: Primarni klinični dokaz za učinkovitost kangrelorja je izpeljan iz študije CHAMPION PHOENIX, ki je bila randomizirana, dvojno slepa študija primerjave kangrelorja (n = 5.472) s klopidogrelom (n = 5.470), oba uporabljena v kombinaciji z acetilsalicilno kislino ali drugim standardnim zdravljenjem, vključno z nefrakcioniranim heparinom (78 %), bivalirudinom (23 %),
English: Mild w/o ecchymosis, oozing and haematoma <5 cm 98 (1.8) Patients with any transfusion
Slovenian: Blaga brez ekhimoze, izcejanja in hematoma < 5 cm 98 (1,8) Bolniki brez vsakršne transfuzije
English: Significant reductions in death/MI/IDR/ST and ST observed in the cangrelor group at 48 hours were maintained at 30 days (Table 4).
Slovenian: V skupini s kangrelorjem so po 48 urah opazili značilno zmanjšanje smrti/MI/IDR/ST in ST, ki se je po 30 dneh ohranilo (preglednica 4).
English: Ecchymosis (petechiae, purpura)
Slovenian: Bolezni kože in podkožja ekhimoza (petehije, purpura)
English: Patients can be transitioned from cangrelor to prasugrel when prasugrel is administered immediately following discontinuation of the cangrelor infusion or up to one hour before, optimally at 30 minutes before the end of the cangrelor infusion to limit recovery of platelet reactivity.
Slovenian: Prehod bolnikov s kangrelorja na prasugrel se lahko opravi tako, da se da prasugrel takoj po prekinitvi infundiranja kangrelorja ali do eno uro prej, optimalno 30 minut pred prenehanjem infundiranja kangrelorja, da se omeji povrnitev sposobnosti odziva trombocitov.
English: Bleeding is a common side effect of treatment with Kengrexal (may affect up to 1 in 10 people).
Slovenian: Krvavitev je pogost neželeni učinek zdravljenja z zdravilom Kengrexal (pojavi se lahko pri največ 1 od 10 bolnikov).
English: A higher rate of serious cases of hypersensitivity were recorded with cangrelor (0.05%) than with control (0.007%).
Slovenian: Poročali so o višji stopnji resnih preobčutljivostnih primerov pri kangrelorju (0,05 %) kot pri kontrolni skupini (0,007 %).
English: Irrespective of dose, following cessation of the infusion, blood levels decrease rapidly and platelet function returns to normal within one hour.
Slovenian: Ne glede na odmerek se po prenehanju infundiranja ravni v krvi hitro zmanjšajo in delovanje trombocitov se v eni uri vrne na normalno.
English: In patients with severe renal impairment (creatinine clearance 15-30 mL/min) a higher rate of worsening in renal function (3.2%) was reported in the cangrelor group compared to clopidogrel (1.4%).
Slovenian: Pri bolnikih s hudo okvaro ledvic (očistek kreatinina 15-30 ml/min) so v skupini s kangrelorjem poročali o višji stopnji poslabšanja delovanja ledvic (3,2 %) v primerjavi s klopidogrelom (1,4 %).
English: Platelet function is restored within 60 minutes of stopping infusion.
Slovenian: Delovanje trombocitov se vzpostavi v 60 minutah po prenehanju infundiranja.
English: What Kengrexal is and what it is used for What you need to know before you use Kengrexal How to use Kengrexal
Slovenian: Kaj je zdravilo Kengrexal in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Kengrexal Kako uporabljati zdravilo Kengrexal Možni neželeni učinki
English: Kengrexal is only for use in adults.
Slovenian: Zdravilo Kengrexal je namenjeno le odraslim.
English: A pharmacodynamic interaction study has also been conducted with cangrelor and ticagrelor.
Slovenian: Študijo farmakodinamičnega medsebojnega delovanja so izvedli tudi s kangrelorjem in tikagrelorjem.
English: • swollen face.
Slovenian: • otekel obraz.
English: In rabbits, cangrelor was associated with increased incidences of abortion and intrauterine losses, as well as foetal growth retardation at higher doses which may have been secondary to maternal toxicity.
Slovenian: Pri kuncih je bil kangrelor pri višjih odmerkih povezan z večjimi incidencami abortusa in znotrajmaterničnih izgub ter zaostalostjo rasti zarodka, kar je morda posledica toksičnosti za mater.
English: A pharmacodynamic interaction study has been conducted with cangrelor and prasugrel, which demonstrated that cangrelor and prasugrel can be administered concomitantly.
Slovenian: Študija farmakodinamičnega medsebojnega delovanja, izvedena s kangrelorjem in prasugrelom, je pokazala, da se lahko kangrelor in prasugrel uporabljajta sočasno.
English: In clinical studies, cangrelor has been co-administered with bivalirudin, low molecular weight heparin, fondaparinux, and GP IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) with no apparent effect upon the pharmacokinetics or pharmacodynamics of cangrelor.
Slovenian: V kliničnih študijah so kangrelor dajali sočasno z bivalirudinom, nizkomolekularnim heparinom, fondaparinuksom in zaviralci GP IIb/IIIa (abciksimab, eptifibatid, tirofiban) brez opaznega učinka na farmakokinetiko ali farmakodinamiko kangrelorja.
English: This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially ‘sodiumfree'.
Slovenian: To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na vialo, kar v bistvu pomeni 'brez natrija'.
English: Kengrexal is not recommended for use during pregnancy.
Slovenian: Zdravila Kengrexal ni priporočljivo uporabljati med nosečnostjo.
English: The bolus volume should be administered rapidly (<1 minute), from the diluted bag via manual intravenous push or pump.
Slovenian: Bolusni volumen je treba dati hitro (< 1 minuta) iz razredčene vreče s pomočjo ročnega intravenskega vbrizga ali črpalke.
English: Talk to your doctor before using Kengrexal if:
Slovenian: Pred začetkom uporabe zdravila Kengrexal se posvetujte z zdravnikom, če:
English: Mild w/o ecchymosis, oozing and haematoma <5 cm 707 (5.6) Patients with any transfusion
Slovenian: Blaga brez ekhimoze, izcejanja in hematoma < 5 cm 707 (5,6) Bolniki brez vsakršne transfuzije
English: Cardiac tamponade
Slovenian: Srčna tamponada
English: In the pooled safety population from the CHAMPION trials, the incidence of fatal bleeding within 30 days of dosing was low and similar in patients who received cangrelor compared to clopidogrel (8 [0.1%] vs. 9 [0.1%]).
Slovenian: V združeni populaciji za preučitev varnosti iz preskušanj CHAMPION je bila incidenca smrtnih krvavitev v 30 dneh od odmerjanja nizka in pri bolnikih, ki so prejeli kangrelor, podobna v primerjavi s klopidogrelom (8 [0,1 %] v primerjavi z 9 [0,1 %]).
English: CABG: Coronary Artery Bypass Graft Surgery; GUSTO: Global Use of Strategies to Open Coronary Arteries; w/o: without a In the CHAMPION pooled analysis, GUSTO Mild was defined as other bleed not requiring blood transfusion or causing haemodynamic compromise.
Slovenian: CABG: kirurški poseg aortokoronarnega obvoda (Coronary Artery Bypass Graft); GUSTO: Globalna uporaba strategij za odpiranje okludiranih arterij (Global Use of Strategies to Open Occluded Arteries) a V združeni analizi CHAMPION je bil blagi dogodek GUSTO opredeljen kot druga krvavitev, zaradi katere ni bila potrebna transfuzija krvi, in ki ni ogrozila hemodinamike.
English: • rash, pruritus, urticaria,
Slovenian: • izpuščaj, pruritus, urtikarija;
English: Table 1: Adverse reactions for cangrelor in CHAMPION pooled studies within 48 hours System organ class
Slovenian: Preglednica 1: Neželeni učinki za kangrelor v združenih študijah CHAMPION v 48 urah
English: Reconstituted solution: the powder should be reconstituted immediately prior to dilution and use.
Slovenian: Rekonstitutirana raztopina: prašek je treba rekonstituirati tik pred redčenjem in uporabo.
English: • bleeding from the penis, ear or pre-existing skin tumours.
Slovenian: • močna menstrualna krvavitev; • krvavitev iz penisa, ušesa ali obstoječih kožnih tumorjev.
English: Table 2: Non-CABG-related bleeding GUSTO bleeding, n (%) CHAMPION pooled
Slovenian: Preglednica 2: Krvavitve, ki niso povezane s CABG Krvavitev GUSTO, n (%)
English: Injury to the urinary tract was reversible following cessation of dosing in an investigative study in rats.
Slovenian: Poškodovanje sečil je bilo po prenehanju dajanja zdravila podganam v raziskovalni študiji reverzibilno.
English: Most dyspnoea events were mild or moderate in severity and the median duration of dyspnoea was two hours in patients receiving cangrelor (see section 4.8).
Slovenian: Večina dogodkov dispneje je bila po resnosti blagih ali zmernih in mediana trajanja dispneje pri bolnikih, ki so prejeli kangrelor, je bila dve uri (glejte poglavje 4.8).
English: How to use Kengrexal
Slovenian: Kako uporabljati zdravilo Kengrexal
English: Cangrelor should be used with caution in patients taking medicines that may increase the risk of bleeding.
Slovenian: Kangrelor je treba pri bolnikih, ki jemljejo zdravila, ki lahko povečajo tveganje za krvavitev, uporabljati previdno.
English: No interaction on cangrelor was observed.
Slovenian: Medsebojnega delovanja s kangrelorjem niso opazili.
English: - If you have recently undergone major surgery or suffered from any form of serious physical trauma such as a bone fracture or road traffic accident.
Slovenian: - če ste imeli nedavno velik kirurški poseg ali ste utrpeli kakršno koli resno telesno poškodbo,
English: A reversible effect on fertility was observed in male rats treated with Kengrexal (see section 5.3).
Slovenian: Pri podganjih samcih, ki so dobivali zdravilo Kengrexal, so opazili reverzibilni učinek na plodnost (glejte poglavje 5.3).
English: The recommended dose of Kengrexal for patients undergoing PCI is a 30 micrograms/kg intravenous bolus followed immediately by 4 micrograms/kg/min intravenous infusion.
Slovenian: Priporočeni odmerek zdravila Kengrexal za bolnike med PKI je intravenski bolus 30 mikrogramov/kg, ki mu takoj sledi intravenska infuzija 4 mikrograme/kg/min.
English: Cangrelor produced dose-related foetal growth retardation characterised by increased incidences of incomplete ossification and unossified hind limb metatarsals in rats.
Slovenian: Kangrelor povzroča od odmerka odvisno zaostalost rasti zarodka, za katero so značilne večje incidence nepopolne osifikacije in nezakostenele metatarzalne kosti zadnjih tac pri podganah.
English: The primary adverse effects of cangrelor in rats and dogs occurred in the upper urinary tract and consisted of injury to renal tubules, renal pelvis, and ureter.
Slovenian: Primarni neželeni učinki kangrelorja pri podganah in psih so se pojavili v zgornjih sečilih v obliki poškodovanja ledvičnih tubulov, ledvičnega meha in sečevoda.
English: Cangrelor should be used with caution in patients with disease states associated with an increased bleeding risk.
Slovenian: Kangrelor je treba pri bolnikih z boleznimi, pri katerih je tveganje za krvavitev povečano, uporabljati previdno.
English: Haematuria, blood urine present, urethral haemorrhage.
Slovenian: hematurija, prisotnost krvi v urinu, krvavitev iz sečnice f.
English: Irrespective of dose, following cessation of the infusion, cangrelor blood levels decrease rapidly and platelet function returns to normal within one hour.
Slovenian: Ne glede na odmerek se po prenehanju infundiranja ravni kangrelorja v krvi hitro zmanjšajo in delovanje trombocitov se v eni uri vrne na normalno.
English: Key Secondary Endpoint
Slovenian: Ključni sekundarni opazovani dogodek
English: Kengrexal should be administered via an intravenous line.
Slovenian: Zdravilo Kengrexal se daje prek intravenske linije.
English: Effects on fertility, ability to produce a pregnancy with female partner(s), sperm morphology and sperm motility were observed in the male rat fertility study when cangrelor was administered at human equivalent doses equal to 1.8 fold the recommended PCI dose.
Slovenian: V študiji plodnosti pri podganjih samcih so opazili učinke na sposobnost razmnoževanja, sposobnost zaploditi samico(e), morfologijo sperme in gibljivost sperme, ko so kangrelor dajali v odmerkih, ki so ustrezali 1,8-kratniku priporočenega odmerka za PKI pri človeku.
English: Start the infusion immediately after administration of the bolus.
Slovenian: Z infundiranjem začnite takoj po dajanju bolusa.
English: Diluted solution: From a microbiological point of view, unless the method of reconstitution/dilution precludes the risk of microbiological contamination, the product should be used immediately.
Slovenian: Razredčena raztopina: Z mikrobiološkega vidika je treba zdravilo porabiti takoj, razen če metoda rekonstitucije/redčenja izključuje tveganje mikrobne kontaminacije.
English: Kengrexal diminishes the clumping of platelets and so reduces the chance of a blood clot forming.
Slovenian: Zdravilo Kengrexal zmanjša zlepljanje trombocitov, s čimer zmanjša možnost nastanka krvnega strdka.
English: When administered in the PCI setting, cangrelor was associated with a greater incidence of GUSTO mild bleeding compared with clopidogrel.
Slovenian: Pri dajanju v povezavi s PCI je bil kangrelor povezan z večjo incidenco blagih krvavitev po lestvici
English: Kengrexal is for injection, followed by infusion (drip), into a vein.
Slovenian: Zdravilo Kengrexal se injicira, nato pa sledi infuzija (kapanje) v veno.
English: When clopidogrel is administered during infusion of cangrelor, the expected inhibitory effect of clopidogrel on platelets is not achieved.
Slovenian: Pri dajanju klopidogrela med infundiranjem kangrelorja pričakovani zaviralni učinek klopidogrela na trombocite ni dosežen.
English: Elimination
Slovenian: Odstranjevanje
English: There are no or limited amount of data from the use of Kengrexal in pregnant women.
Slovenian: Podatkov o uporabi zdravila Kengrexal pri nosečnicah ni oziroma so omejeni.
English: Cangrelor did not produce malformations in either the rat or rabbit reproductive studies.
Slovenian: Kangrelor ni povzročil malformacij niti v študijah sposobnosti razmnoževanja pri podganah niti pri kuncih.
English: Pharmacokinetic/pharmacodynamic relationship(s)
Slovenian: Farmakokinetično/farmakodinamično razmerje Posebne populacije
English: Cangrelor is contraindicated in patients with any history of stroke/TIA, (see sections 4.3 and 4.8).
Slovenian: Kangrelor je kontraindiciran pri bolnikih z možgansko kapjo/TIA v anamnezi, (glejte poglavji 4.3 in 4.8).
English: Name and address of the manufacturer(s) responsible for batch release
Slovenian: SPROŠČANJE SERIJ Ime in naslov proizvajalca (proizvajalcev), odgovornega (odgovornih) za sproščanje serij
English: Kengrexal is administered as a weight-based regimen consisting of an initial intravenous bolus followed by an intravenous infusion.
Slovenian: Zdravilo Kengrexal se daje kot režim na podlagi telesne mase v obliki začetnega intravenskega bolusa, ki mu sledi intravenska infuzija.
English: For transition, a loading dose of oral P2Y12 therapy (clopidogrel, ticagrelor or prasugrel) should be administered immediately following discontinuation of cangrelor infusion.
Slovenian: Pri prehodu je treba dati začetni odmerek peroralne terapije P2Y12 (klopidogrel, tikagrelor ali prasugrel), ki mora slediti takoj po končanem infundiranju kangrelorja.
English: No effect on female fertility parameters were observed in animal studies of Kengrexal.
Slovenian: Študije na živalih z zdravilom Kengrexal niso pokazale vpliva na parametre sposobnosti razmnoževanja pri ženskah.
English: The GUSTO bleeding scale was measured in the CHAMPION (PHOENIX, PLATFORM, and PCI) clinical trials.
Slovenian: V kliničnih preskušanjih CHAMPION (PHOENIX, PLATFORM in PCI) so krvavitev merili po lestvici GUSTO.
English: • reduced clotting of the blood,
Slovenian: • zmanjšano strjevanje krvi;
English: Powder for concentrate for solution for injection/infusion 10 vials
Slovenian: prašek za koncentrat za raztopino za injiciranje/infundiranje 10 vial
English: Non-clinical data reveal no special safety risk for humans based on studies of safety pharmacology, mutagenicity and clastogenic potential.
Slovenian: Predklinični podatki na osnovi študij farmakološke varnosti, mutagenosti in klastogenosti ne kažejo posebnega tveganja za človeka.
English: No pharmacokinetic or pharmacodynamic interaction with cangrelor was observed in an interaction study with aspirin, heparin, or nitroglycerin.
Slovenian: Farmakokinetičnega ali farmakodinamičnega medsebojnega delovanja kangrelorja z acetilsalicilno kislino, heparinom ali nitroglicerinom v študiji medsebojnega delovanja niso opazili.
English: Cerebral haemorrhage, cerebrovascular accident.
Slovenian: cerebralna krvavitev, cerebrovaskularni inzult e.
English: Effects on renal function
Slovenian: Učinki na delovanje ledvic
English: The most common adverse reactions with cangrelor include mild and moderate bleeding and dyspnoea.
Slovenian: Najpogostejši neželeni učinki s kangrelorjem vključujejo blago do zmerno krvavitev in dispnejo.
English: Kengrexal is an anti-platelet medicine that contains the active substance cangrelor.
Slovenian: Zdravilo Kengrexal je antitrombotik, ki vsebuje zdravilno učinkovino kangrelor.
English: • dyspnoea (shortness of breath),
Slovenian: • dispneja (kratka sapa);
English: Hepatic impairment No dose adjustment is needed (see section 5.2).
Slovenian: Odmerka ni treba prilagajati (glejte poglavje 5.2).